Arrhythmias & electrophysiologyCohort study
Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: the STOPSTORM.eu study
- Prospective multicentre registry study
- international
- planned interim analysis
- Median follow-up 19 months
Authors' conclusion
In the largest prospective multicentre cohort reported to date, STAR was associated with a substantial reduction in VT burden and ICD shocks, with a low frequency of possibly or probably treatment-related SAEs.
Study context
- Population
- Patients with refractory ventricular tachycardia (VT) treated with stereotactic arrhythmia radioablation (STAR), 28 European centres107 evaluable
- Participants
- 193 patients
- Exposure
- 6 months before vs 6 months after STAR
- Outcome
- Change in sustained VT episode burden, 6 months before vs 6 months after STAR
- Follow-up
- 6 months
Main finding
As reported in the abstract
Median VT episode burden
Median VT episode burden reduced after STAR
80%
Observational data: associations, not effects.
Further findings
Freedom from implantable cardioverter-defibrillator (ICD) shock (patients surviving ≥6 months)
- Free from ICD shock
- 72%
Overall survival · 12 months
- Overall survival probability
- 77%
Safety
Serious adverse events (SAEs) possibly or probably treatment-related (primary safety endpoint)
- Treatment-related SAEs in full cohort, incl. pericardial effusion, coronary events, early post-treatment ventricular arrhythmia
- 12
Original publication
Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: the STOPSTORM.eu study. Eur Heart J. Published 20 April 2026. doi:10.1093/eurheartj/ehag338
Summarised from the published abstract; every number is checked against it